Sugi Predict

Sugi Predict / Compounds / SCHEMBL588627

SCHEMBL588627

SCHEMBL588627

Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2ccccn12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 20/20 1.00
▸ ABL2 P42684 4/20 0.85
▸ MAPK14 Q16539 2/20 0.79
▸ GAK O14976 1/20 0.79
▸ MLNR O43193 1/20 0.79
▸ RIPK2 O43353 1/20 0.79
▸ JAK2 O60674 1/20 0.79
▸ NR1I2 O75469 1/20 0.79
▸ ABCB11 O95342 1/20 0.79
▸ MAP4K4 O95819 1/20 0.79
▸ EGFR P00533 1/20 0.79
▸ NR3C1 P04150 1/20 0.79
▸ ERBB2 P04626 1/20 0.79
▸ NTRK1 P04629 1/20 0.79
▸ LCK P06239 1/20 0.79
▸ FYN P06241 1/20 0.79
▸ PGR P06401 1/20 0.79
▸ CSF1R P07333 1/20 0.79
▸ YES1 P07947 1/20 0.79
▸ LYN P07948 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29493478 1.00 ABL1 (1.00) ABL1ABL2MAPK14GAKMLNR
SCHEMBL10207569 0.97 ABL1 (1.00) ABL1ABL2MAPK14GAKMLNR
SCHEMBL9610993 0.97 ABL1 (1.00) ABL1ABL2MAPK14GAKMLNR
SCHEMBL9611125 0.94 ABL1 (1.00) ABL1ABL2MAPK14GAKMLNR
SCHEMBL22243491 0.94 ABL1 (0.90) ABL1ABL2MAPK14GAKMLNR
SCHEMBL9610987 0.94 ABL1 (1.00) ABL1ABL2MAPK14GAKMLNR
SCHEMBL9610990 0.94 ABL1 (1.00) ABL1ABL2MAPK14GAKMLNR
SCHEMBL9611034 0.94 ABL1 (0.90) ABL1ABL2MAPK14GAKMLNR
SCHEMBL15061759 0.93 ABL1 (0.87) ABL1ABL2MAPK14GAKMLNR
SCHEMBL9610799 0.93 ABL1 (0.87) ABL1ABL2MAPK14GAKMLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3417912-B1 BICYCLIC HETEROARYL COMPOUNDS ARIAD PHARMA INC (US) 2020-08-12 — — EP claimed
EP-3417912-A1 BICYCLIC HETEROARYL COMPOUNDS ARIAD Pharmaceuticals, Inc. (US) 2018-12-26 — — EP claimed
CN-103044432-B Bicyclic heteroaryl compounds 阿里亚德医药股份有限公司 2016-08-03 — — CN claimed
US-20150105377-A1 Methods and Compositions for RAF Kinase Mediated Diseases ARIAD PHARMACEUTICALS, INC. 2015-04-16 — — US claimed
EP-2841062-A1 METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES ARIAD PHARMACEUTICALS, INC. (US) 2015-03-04 — — EP claimed
CN-103596568-A Methods and compositions for treating Parkinson disease ARIAD PHARMA INC 2014-02-19 — — CN claimed
US-20140045826-A1 METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES ARIAD PHARMACEUTICALS, INC. (US) 2014-02-13 — — US claimed
EP-2694066-A1 METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE ARIAD Pharmaceuticals, Inc (US) 2014-02-12 — — EP claimed
CN-103582478-A Methods and compositions for treating neurodegenerative diseases ARIAD PHARMA INC 2014-02-12 — — CN claimed
WO-2013162727-A1 METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES ARIAD PHARMACEUTICALS, INC. (US) 2013-10-31 — — WO claimed
US-20130231337-A1 Bicyclic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-09-05 — — US claimed
WO-2013101281-A1 METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE ARIAD PHARMACEUTICALS, INC. (US) 2013-07-04 — — WO claimed
US-8470851-B2 Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2013-06-25 — — US claimed
EP-1973545-B1 BICYCLIC HETEROARYL COMPOUNDS ARIAD PHARMA INC (US) 2013-01-30 — — EP claimed
US-20250361232-A1 SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICALS USA INC (US) 2025-11-27 — — US disclosed
WO-2023114759-A2 ABL INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-22 — — WO disclosed
US-20220081440-A1 SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICALS U.S.A., INC. 2022-03-17 — — US disclosed
CN-101389338-A Bicyclic heteroaryl compounds ARIAD PHARMA INC (US) 2009-03-18 — — CN disclosed
US-20070191376-A1 Bicyclic heteroaryl compounds TAKEDA PHARMACEUTICALS U.S.A., INC. 2007-08-16 — — US disclosed
US-20070191376-A1 Bicyclic heteroaryl compounds TAKEDA PHARMACEUTICALS U.S.A., INC. 2007-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220081440-A1 SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS MAP4K2, MAP3K19, MAP3K1 ABL1 122/4885ABL2 328/4885MAPK14 35/4885
US-20150105377-A1 Methods and Compositions for RAF Kinase Mediated Diseases BRAF, RAF1, NRAS ABL1 75/4885ABL2 231/4885MAPK14 199/4885
US-20070191376-A1 Bicyclic heteroaryl compounds CYP3A43, CYP11B2, CYP2F1 ABL1 110/4885ABL2 1006/4885MAPK14 4516/4885
US-20140045826-A1 METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA ABL1 4036/4885ABL2 3737/4885MAPK14 2888/4885
US-20130231337-A1 Bicyclic Heteroaryl Compounds CYP3A43, CYP11B2, CYP2F1 ABL1 110/4885ABL2 1006/4885MAPK14 4516/4885
US-20250361232-A1 SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS MAP4K2, MAP3K19, MAP3K1 ABL1 122/4885ABL2 328/4885MAPK14 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.